Sort by

Send to:

Choose Destination

Results: 5


A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x. Epub 2014 Sep 22.


Current status of co-occurring mood and substance use disorders: a new therapeutic target.

Pettinati HM, O'Brien CP, Dundon WD.

Am J Psychiatry. 2013 Jan;170(1):23-30. doi: 10.1176/appi.ajp.2012.12010112. Review.


A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP.

Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.


Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial.

Fairbairn CE, Dundon WD, Xie H, Plebani JG, Kampman KM, Lynch KG.

Am J Addict. 2008 Sep-Oct;17(5):387-91. doi: 10.1080/10550490802266078.


The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence.

Dundon WD, Pettinati HM, Lynch KG, Xie H, Varillo KM, Makadon C, Oslin DW.

Drug Alcohol Depend. 2008 Jun 1;95(3):230-6. doi: 10.1016/j.drugalcdep.2008.01.010. Epub 2008 Mar 10.

Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk